Barclays PLC Grows Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Barclays PLC raised its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 29.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 218,455 shares of the biotechnology company’s stock after purchasing an additional 50,109 shares during the quarter. Barclays PLC’s holdings in Heron Therapeutics were worth $434,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. The Manufacturers Life Insurance Company raised its holdings in shares of Heron Therapeutics by 16.0% in the second quarter. The Manufacturers Life Insurance Company now owns 45,771 shares of the biotechnology company’s stock worth $160,000 after buying an additional 6,328 shares during the period. nVerses Capital LLC purchased a new stake in Heron Therapeutics in the second quarter worth $27,000. Wealth Enhancement Advisory Services LLC lifted its position in shares of Heron Therapeutics by 21.2% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 45,273 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 7,927 shares during the last quarter. King Wealth Management Group boosted its stake in shares of Heron Therapeutics by 52.3% during the third quarter. King Wealth Management Group now owns 23,299 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 8,000 shares during the period. Finally, Glenmede Trust Co. NA grew its holdings in shares of Heron Therapeutics by 49.6% in the third quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 10,578 shares during the last quarter. Institutional investors own 80.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on HRTX shares. Needham & Company LLC reiterated a “buy” rating and set a $4.00 price objective on shares of Heron Therapeutics in a report on Wednesday, December 4th. StockNews.com downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday.

Heron Therapeutics Trading Up 3.7 %

Shares of Heron Therapeutics stock opened at $1.66 on Friday. The stock’s fifty day moving average price is $1.51 and its 200-day moving average price is $2.07. The firm has a market cap of $252.48 million, a P/E ratio of -9.22 and a beta of 1.60. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, meeting analysts’ consensus estimates of ($0.03). The business had revenue of $32.81 million for the quarter, compared to analysts’ expectations of $36.40 million. During the same period last year, the business posted ($0.17) EPS. Analysts forecast that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.